DRDO develops 5.56x45 mm CQB carbine in partnership with private sector firm
New Delhi [India], June 23 (ANI): In a significant development, a Carbine developed by the Defence Research and Development Organisation (DRDO) has emerged as the lowest bidder in the Indian Army tender for buying over 4 lakh close-quarter battle carbines for operations.
DRDO Develops 5.56x45 mm CQB Carbine
'Significantly boosting #atmanirbharta in critical technology, 5.56x45 mm CQB Carbine, designed and developed by Armament Research and Development Establishment(ARDE), DRDO selected as L1 in Indian Army Request for Proposal (RFP)', DRDO shared on 'X'.
The Indian Army has been looking to acquire these carbines for a long time, but has not been able to make any progress due to the withdrawal of tenders.
If the Indian Army finally signs the tender for buying the carbines, this would be one of the biggest contracts ever for Indian-designed and developed small arms.
Meanwhile on June 17, India entered into a new quantum era by successfully demonstrating an experimental advancement through DRDO-Industry-Academia Centre of Excellence (DIA-CoE), IIT Delhi, according to the official statement from the Ministry of Defence.
Free-space quantum secure communication using quantum entanglement over a distance of more than one km was achieved via a free-space optical link established on the IIT Delhi campus.
The experiment attained a secure key rate of nearly 240 bits per second with a quantum bit error rate of less than 7 per cent.As per the release, this entanglement-assisted quantum secure communication paves the way for real-time applications in quantum cybersecurity, including long-distance Quantum Key Distribution (QKD), the development of quantum networks, and the future quantum internet.
These efforts align with India's broader objectives to advance quantum technologies for national development.
Under the project 'Design and development of photonic technologies for free space QKD', sanctioned by Directorate of Futuristic Technology Management (DFTM), DRDO, the demonstration was given by Prof Bhaskar Kanseri's research group in the presence of several dignitaries, including the DRDO DG (MED, COS & CS), Director SAG, Director DFTM, Dean (R&D) IIT Delhi, Director (DIA-CoE) and DRDO laboratory scientists. (ANI)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
22 minutes ago
- Time of India
How dengue mosquitoes outsmart even scientists
How dengue mosquitoes outsmart even scientists - their secret hunting techniques revealed Chethan Kumar TNN Updated: Jun 23, 2025, 18:12 IST IST While the dengue mosquito is a smarter predator than previously thought — it can detect you with its legs, too — Indian scientists have detected that a stealthy group of immune cells could be the unsung heroes in fighting the infection It's tough to outsmart a mosquito out for your blood. Here's some consolation. The buzzing insect outsmarts even supersmart scientists. 'Aedes aegypti', the mosquito behind dengue , Zika, and yellow fever , hunts down its prey — humans — primarily by its sense of smell. So, when researchers from the Rockefeller University stripped Aedes aegypti of its primary olfactory gene, Orco — knocking out their sense of smell — they reckoned the female mosquito will lose her hunting instinct. But she was smarter than they were. As a new study published in Science Advances details, when deprived of their olfactory power, Aedes use their ability to sense body heat. Typically, it's the mosquito's antennae that detects odours and heat. But Orco mutants deploy their forelegs to detect human skin temperature.
&w=3840&q=100)
Business Standard
29 minutes ago
- Business Standard
Gene-edited rice may pose IPR risks, scientists say in letter to PM
A group of scientists calling themselves the 'Agricultural Scientists Manch' have written to the Prime Minister denouncing the recent release of India's first genetically edited rice varieties, stating that the technology used—CRISPR-Cas9—could face intellectual property rights (IPR) issues, potentially negating the real advantage Indian farmers could derive from genome-edited rice. The Centre has repeatedly clarified that all IPR issues related to gene editing are being thoroughly addressed, and a panel has been formed for this purpose. It has also assured that the government will acquire the necessary licences for gene-editing technologies and that no additional burden will fall on Indian farmers. The letter, signed by nearly 20 former and current scientists including Sharad Nimbalkar, former vice-chancellor of Panjabrao Deshmukh Agriculture University, Akola, stated that although CRISPR-Cas9 is a highly precise technology, it can still go off-track, potentially causing severe undesirable consequences. It also warned that large-scale use of gene-edited rice could contaminate India's native rice germplasm. The scientists further expressed concern that unresolved IPR issues could lead to Indian farmers becoming dependent on foreign seed technologies. They added that the newly released rice varieties were cleared without adequate evaluation. The letter was also marked to Agriculture Minister Shivraj Singh Chouhan, Environment Minister Bhupender Yadav, Health Minister Jagat Prakash Nadda and Science and Technology Minister Jitendra Singh. Last month, in a significant development, the government released two genome-edited rice varieties for the first time in the country. These varieties are expected to increase per-hectare yields by up to 30 per cent and mature 15–20 days earlier than existing varieties.
Mint
an hour ago
- Mint
Meril Launches MyClip, Transcatheter-Edge-to-Edge Repair (TEER) System in India
Meril Life Sciences, a global med-tech company, launched MyClip, a Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The Structural Heart Innovation event, held at Meril Academy, Vapi, Gujarat, from June 13–15, 2025, gathered over 150 Indian interventional cardiologists,cardiac imaging experts and international figures such as Prof. Ottavio Alfieri, Prof. Francesco Maisano, and Prof. Agricola. The introduction to MyClip indicates developments in structural heart solutions in India and reflects Meril's commitment to accessible cutting-edge cardiac care. MyClip TEER System is designed for patients with severe Mitral Regurgitation (MR) who face high surgical risk due to conditions such as hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. Untreated MR can have a significant mortality rate, with over 50% of patients not surviving without timely intervention, and a one-year mortality rate that can reach 57%. The MyClip TEER System allows for the precise closure of the mitral valve flaps, which can help prevent the backward flow of purified blood into the lungs. The procedure is minimally invasive, typically lasts about an hour, and may allow patients to return home within 3–5 days. Following discharge, patients may resume daily activities like walking and non-strenuous work relatively soon after the procedure. The COAPT Study, published in the New England Journal of Medicine (NEJM), reported that patients who received device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalisation rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control group. Currently, approximately 150 TEERprocedures are performed annually in India, with the majority of patients falling in the age group of 30 to 60 years. These statistics bring to light a pressing need for early and effective intervention in younger demographics. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country." 'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai with brand ambassador MS Dhoni aims to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Mr. Bhatt added. The two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and presentations by leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous innovation.
